Cdk9 Inhibitors
Items 11 to 17 of 17 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cdk/Crk Inhibitor | 784211-09-2 | sc-203872 | 1 mg | $290.00 | ||
Cdk/Crk Inhibitor is a selective modulator of Cdk9, distinguished by its unique ability to disrupt the enzyme's phosphorylation cascade. By forming specific hydrogen bonds with key residues in the active site, it induces a conformational shift that impedes substrate access. This inhibitor also alters the dynamics of protein-protein interactions, impacting cellular signaling networks and transcriptional regulation. Its kinetic profile reveals a rapid onset of action, underscoring its potential for fine-tuning cellular processes. | ||||||
AT7519 | 844442-38-2 | sc-364416 sc-364416A sc-364416B sc-364416C | 5 mg 10 mg 100 mg 1 g | $291.00 $341.00 $1046.00 $3126.00 | 1 | |
AT7519 is a multi-CDK inhibitor that includes Cdk9 in its targets. It can inhibit RNA polymerase II phosphorylation and the subsequent transcription process. | ||||||
CR8, (S)-Isomer | 1084893-56-0 | sc-311307 | 5 mg | $201.00 | ||
CR8, the (S)-isomer, exhibits remarkable selectivity for Cdk9, characterized by its ability to stabilize an inactive conformation of the enzyme. This stabilization is achieved through unique hydrophobic interactions and van der Waals forces with critical amino acid side chains. The compound's kinetic behavior indicates a slow dissociation rate, enhancing its efficacy in modulating Cdk9 activity. Additionally, CR8 influences downstream signaling pathways by altering the phosphorylation status of target proteins, thereby affecting cellular homeostasis. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib is a potent CDK inhibitor with activity against Cdk9. By inhibiting Cdk9, it can prevent the phosphorylation of RNA polymerase II and transcription elongation. | ||||||
Cdk2/9 Inhibitor Inhibitor | 507487-89-0 | sc-221411 | 5 mg | $416.00 | 1 | |
Cdk2/9 Inhibitor demonstrates a distinctive mechanism of action by selectively binding to the ATP-binding pocket of Cdk9, leading to a conformational shift that inhibits its kinase activity. This compound engages in specific hydrogen bonding and electrostatic interactions with key residues, resulting in a prolonged inhibition effect. Its unique reaction kinetics reveal a non-competitive inhibition profile, allowing for nuanced modulation of transcriptional regulation and cellular processes. | ||||||
R547 | 741713-40-6 | sc-364596 sc-364596A | 2 mg 5 mg | $375.00 $395.00 | ||
R-547 is a pan-CDK inhibitor that targets multiple CDKs, including Cdk9. This can result in the inhibition of RNA polymerase II phosphorylation. | ||||||
PHA-793887 | 718630-59-2 | sc-364580 sc-364580A | 5 mg 10 mg | $189.00 $432.00 | ||
PHA-793887 inhibits various CDKs, including Cdk9. Its inhibition can disrupt transcription elongation by blocking Cdk9 activity. | ||||||